在急性心力衰竭患者中,前腺腺素与拥堵有关
Benedikt N Beer1,2, Saman Keshtkaran1, Caroline Kellner1,3
1Department of Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ESC heart failure
|August 20, 2024
概括
在急性心力衰竭患者中,中区域前腺腺素水平升高表明严重的拥堵. 这种生物标志物与心力衰竭的恶化和死亡风险的增加有关,这表明它有可能指导治疗.
科学领域:
- 心脏病学 心脏病学
- 生物标志物 生物标志物
- 急性心力衰竭是指急性心力衰竭
背景情况:
- 拥堵是影响急性心力衰竭 (AHF) 结果的关键因素.
- 准确的拥堵评估是具有挑战性的,这导致了优化脱凝疗法的困难.
- 出院时的残留拥堵与重新住院和死亡率的增加有关.
研究的目的:
- 评估中区域性前腺腺素 (MR-proADM) 作为在AHF中量化拥堵的客观标志物.
- 评估MR-proADM与临床结果的关联,包括住院死亡,出院后的死亡率和住院恶化的心力衰竭.
- 探索MR-proADM在指导AHF患者的脱血疗法的潜力.
主要方法:
- 一项前性,观察性,单中心研究,涉及233名未经选择的AHF患者.
- 在基线和出院时测量了MR-proADM水平;使用临床得分评估了拥堵.
- 统计分析包括考克斯和后勤回归模型,根据临床特征进行调整.
主要成果:
- MR-proADM度与入学和退学时的拥堵有显著的相关性.
- 基线MR-proADM升高与住院心力衰竭恶化有关 (OR4.23,P<0.001).
- 高度放出MR-proADM与放出后死亡相关 (HR 3.93,P < 0.001).
结论:
- 较高的MR-proADM水平与AHF患者的不良结果相关,包括住院恶化和长期死亡率.
- 作为评估拥堵和预测AHF的结果的生物标志物,MR-proADM显示出希望.
- 需要进一步的研究来验证这些发现,并调查MR-proADM在指导脱血治疗策略中的实用性.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Adrenergic Agonists: Therapeutic Uses
756
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
756
Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Adrenergic Agonists: Direct-Acting Agents
1.4K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.4K
Adrenergic Agonists: Therapeutic Classification
757
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
757


